Signaturefd LLC Grows Stock Position in Repligen Co. (NASDAQ:RGEN)

Signaturefd LLC raised its stake in shares of Repligen Co. (NASDAQ:RGENGet Rating) by 37.7% in the first quarter, according to its most recent 13F filing with the SEC. The fund owned 402 shares of the biotechnology company’s stock after buying an additional 110 shares during the period. Signaturefd LLC’s holdings in Repligen were worth $76,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the stock. State Street Corp raised its stake in shares of Repligen by 2.6% during the 4th quarter. State Street Corp now owns 1,347,371 shares of the biotechnology company’s stock valued at $356,838,000 after buying an additional 34,757 shares during the last quarter. Allspring Global Investments Holdings LLC purchased a new position in shares of Repligen in the 4th quarter valued at about $218,643,000. Impax Asset Management Group plc increased its stake in shares of Repligen by 31.6% in the 4th quarter. Impax Asset Management Group plc now owns 813,012 shares of the biotechnology company’s stock valued at $214,295,000 after purchasing an additional 195,300 shares in the last quarter. Conestoga Capital Advisors LLC increased its stake in shares of Repligen by 18.2% in the 1st quarter. Conestoga Capital Advisors LLC now owns 772,719 shares of the biotechnology company’s stock valued at $145,341,000 after purchasing an additional 118,818 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Repligen by 2.4% in the 4th quarter. Geode Capital Management LLC now owns 682,437 shares of the biotechnology company’s stock valued at $180,736,000 after purchasing an additional 16,198 shares in the last quarter. Hedge funds and other institutional investors own 86.82% of the company’s stock.

Insider Transactions at Repligen

In other news, Director Karen A. Dawes sold 14,715 shares of the business’s stock in a transaction that occurred on Wednesday, May 25th. The stock was sold at an average price of $150.51, for a total transaction of $2,214,754.65. Following the transaction, the director now directly owns 76,532 shares in the company, valued at approximately $11,518,831.32. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, CEO Anthony Hunt sold 24,802 shares of the business’s stock in a transaction that occurred on Thursday, July 21st. The stock was sold at an average price of $200.00, for a total transaction of $4,960,400.00. Following the transaction, the chief executive officer now directly owns 194,667 shares in the company, valued at approximately $38,933,400. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Karen A. Dawes sold 14,715 shares of the business’s stock in a transaction that occurred on Wednesday, May 25th. The stock was sold at an average price of $150.51, for a total value of $2,214,754.65. Following the transaction, the director now owns 76,532 shares in the company, valued at $11,518,831.32. The disclosure for this sale can be found here. Insiders own 1.10% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on RGEN. StockNews.com began coverage on Repligen in a research note on Thursday, March 31st. They issued a “hold” rating for the company. Craig Hallum cut their price target on Repligen from $286.00 to $274.00 in a research note on Thursday, April 28th. Finally, UBS Group began coverage on Repligen in a research note on Wednesday, July 20th. They issued a “buy” rating and a $213.00 price target for the company. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $288.86.

Repligen Trading Up 1.8 %

NASDAQ:RGEN opened at $205.71 on Thursday. Repligen Co. has a 12 month low of $137.21 and a 12 month high of $327.32. The stock has a 50 day moving average of $165.02 and a two-hundred day moving average of $172.62. The firm has a market cap of $11.20 billion, a P/E ratio of 81.31 and a beta of 0.95.

Repligen (NASDAQ:RGENGet Rating) last posted its quarterly earnings data on Wednesday, April 27th. The biotechnology company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.72 by $0.20. Repligen had a return on equity of 11.13% and a net margin of 19.86%. The company had revenue of $206.40 million during the quarter, compared to analyst estimates of $185.48 million. During the same period in the previous year, the business earned $0.68 EPS. Repligen’s quarterly revenue was up 44.5% on a year-over-year basis. On average, research analysts forecast that Repligen Co. will post 3.1 earnings per share for the current year.

Repligen Company Profile

(Get Rating)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

See Also

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGENGet Rating).

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.